Galapagos NV has consolidated its drug discovery activities under a new agreement with the French contract research organisation (CRO) NovAliX SAS enabling it to focus on fewer therapeutic areas. Announced on 30 March, the agreement will see NovAliX acquire Galapagos’ research and discovery assets in Romainville, France. Employees of Galapagos at the same site will also transfer to the CRO.
